Recent Updates
Recently added Catalysts
ONC Positive Sentiment Score: 70/100

BeOne Medicines to Announce Fourth Quarter and Full Year 2025 Financial Results on February 26

Key Takeaway: BeOne Medicines Ltd. will announce its fourth quarter and full year 2025 financial results on February 26, 2026, before market opening. Following the announcement, a live webcast will be held at 8:00 a.m. ET. BeOne is focused on developing innovative oncology treatments and has a significant global workforce.

Market Sentiment Analysis

POSITIVE FACTORS

  • BeOne Medicines is expanding its global presence in oncology.
  • The company is committed to making treatments more accessible to cancer patients.
  • A diverse pipeline of novel therapeutics is being developed.

Full Press Release Details

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, will report its fourth quarter and full year 2025 financial results on Thursday, February 26, 2026 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET.
The live webcast of this event can be accessed from the investors section of the Company’s website athttps://ir.beonemedicines.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast. An archived webcast will be available on the Company’s website.
About BeOne MedicinesBeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The Company has a growing global team of nearly 12,000 colleagues spanning six continents who are driven by scientific excellence and exceptional speed to reach more patients than ever before.
To learn more about BeOne, please visitwww.beonemedicines.comand follow us onLinkedIn,X,FacebookandInstagram.
Forward-Looking StatementsThis press release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne’s plans, commitments, aspirations and goals related to BeOne’s medicines and drug candidates. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors which are discussed in the section entitled “Risk Factors” in BeOne’s most recent periodic report filed with the U.S. Securities and Exchange Commission (“SEC”) as well as discussions of potential risks, uncertainties, and other important factors in BeOne’s subsequent filings with the SEC. All information in this press release is as of the date hereof, and BeOne undertakes no duty to update such information unless required by law.

Frequently Asked Questions

When will BeOne Medicines announce its financial results?

BeOne Medicines will announce its fourth quarter and full year 2025 financial results on February 26, 2026.

What time is the live webcast for BeOne's financial results?

The live webcast will take place at 8:00 a.m. ET on February 26, 2026.

How can I access the live webcast?

The live webcast can be accessed from the investors section of BeOne Medicines' website.

What is BeOne Medicines focused on?

BeOne Medicines is focused on discovering and developing innovative oncology treatments.

Last updated: Feb 11, 2026